Citius rises as lymphoma drug shows benefit in patients before CAR-T therapy

Citius Oncology

04/03/2026 15:08

** Shares of drugmaker Citius Oncology CTOR.O rise 1.89% to $1.08

** Co says early data shows its drug Lymphir may benefit patients with aggressive lymphoma, when administered before CAR-T therapy

**  High-risk diffuse large B-cell lymphoma is a fast‑growing blood cancer

** Co says 86% of 14 patients showed improvement after a single Lymphir dose administered before CAR-T, with over half reaching complete remission

**  Mild side effects were reported; all patients were able to proceed with CAR-T, co says

** Lymphir was approved in 2024 to treat certain adult patients with a group of rare blood cancers that affects the skin

** Shares down ~13% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))